Top

Published in:

01-04-2018 | Editorial

Somatostatin and diabetic retinopathy: an evolving story

Authors: Olga Simó-Servat, Cristina Hernández, Rafael Simó

Published in: Endocrine | Issue 1/2018

Excerpt

The story of how somatostatin (SST) has come to play an evolving role in the treatment of diabetic retinopathy (DR) has to be seen in the context of the growth of scientific knowledge regarding the pathophysiology of DR. …

J.D. Poulsen, Diabetes and anterior pituitary deficiency. Diabetes 2, 7–12 (1953)CrossRefPubMed

J.D. Poulsen, Diabetes and anterior pituitary deficiency: final course and postmortem study of a diabetic patient with Sheehan’s syndrome. Diabetes 15, 73–77 (1966)CrossRefPubMed

T.J. Merimee, S.E. Fineberg, V.A. McKusik, J. Hall, Diabetes mellitus and sexual ateliotic dwarfism: comparative study. J. Clin. Invest. 49(6), 1096–1102 (1970)CrossRefPubMedPubMedCentral

P.S. Sharp, T.J. Fallon, O.J. Brazier, L. Sandler, G.F. Joplin, E.M. Kohner, Long term follow-up of patients who underwent ytrum-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 30(4), 199–207 (1987)CrossRefPubMed

E.M. Kohner, G.F. Joplin, R.K. Black, H. Cheng, T.R. Fraser, Pituitary ablation in the treatment of diabetic retinopathy. Trans. Ophthalmol. Soc. U.K. 92, 79–90 (1972)PubMed

M.B. Grant, R.N. Mames, C. Fitzgerald, K.M. Hazariwala, R. Cooper-DeHoff, S. Caballero, K.S. Estes, The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23(4), 504–509 (2000)CrossRefPubMed

B.O. Boehm, G.K. Lang, P.M. Jehle, B. Feldman, G.E. Lang, Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm. Metab. Res. 33(5), 300–306 (2001)CrossRefPubMed

S.S. Palii, S. Caballero, G. Shapiro, M.B. Grant, Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin. Investig. Drugs 16(1), 73–82 (2007)CrossRefPubMed

R. Pivonello, G. Muscogiuri, G. Holder, M. Paul, S. Sarp, A. Lesogor, P. Jordaan, J. Eisinger, A. Colao, Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. Endocrine. https://doi.org/10.1007/s12020-017-1448-5. (2017)

10.

M. Takagi, T. Babazono, Y. Uchigata, Differences in risk factors for the onset of albuminuria and decrease in glomerular filtration in people with Type 2 diabetes mellitus: implications for the pathogenesis if diabetic kidney disease. Diabet. Med. 32(10), 1354–1360 (2015)CrossRefPubMedPubMedCentral

11.

J.R. Brownrigg, C.O. Hughes, D. Burleigh, A. Karthikesalingam, B.O. Patterson, P.J. Holt, M.M. Thompson, S. de Lusignan, K.K. Ray, R.J. Hinchliffe, Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 4(7), 588–597 (2016)CrossRefPubMed

12.

J.F. Payne, V. Tangpricha, J. Cleveland, M.L. Lynn, R. Ray, S.K. Srivastava, Serum insulin-like growth factor-I in diabetic retinopathy. Mol. Vis. 17, 2318–1324 (2011)PubMedPubMedCentral

13.

Q. Wang, D. Dills, R. Klein, B. Klein, S. Moss, Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes 44(2), 161–164 (1995)CrossRefPubMed

14.

Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group, The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108(12), 2266–2272 (2001)CrossRef

15.

S. Azzoug, F. Chentli, Diabetic retinopathy in acromegaly. Indian J. Endocr. Metab. 18(3), 407–409 (2014)CrossRef

16.

R. Simó, E. Carrasco, M. García-Ramírez, C. Hernández, Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr. Diabes. Rev. 2(1), 71–98 (2006)CrossRef

17.

C. Gerhardinger, K.D. McClure, G. Romeo, F. Podesta, M. Lorenzi, IGF-I mRNA and signaling in the diabetic retina. Diabetes 50(1), 175–183 (2001)CrossRefPubMed

18.

C. Hernández, O. Simó-Servat, R. Simó, Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine 46(2), 209–214 (2014)CrossRefPubMed

19.

E. Carrasco, C. Hernández, A. Miralles, P. Huget, J. Farres, R. Simó, Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 30(11), 2902–2908 (2007)CrossRefPubMed

20.

C. Hernández, E. Carrasco, R. Casamitjana, R. Deulofeu, J. García-Arumí, R. Simó, Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and non-diabetic control subjects. Diabetes Care 28(8), 1941–1947 (2005)CrossRefPubMed

21.

C. Hernández, M. García-Ramírez, L. Corraliza, J. Fernández-Carneado, J. Farrera-Sinfreu, B. Ponsati, A. González-Rodríguez, A.M. Valverde, R. Simó, Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 62(7), 2569–2578 (2013)CrossRefPubMedPubMedCentral

22.

C. Hernández, P. Bogdanov, C. Solà-Adell, J. Sampedro, M. Valeri, X. Genís, O. Simó-Servat, M. García-Ramírez, R. Simó, Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia 60(11), 2285–2298 (2017)CrossRefPubMed

23.

C. Hernández, P. Bogdanov, L. Corraliza, M. García-Ramírez, C. Solà-Adell, J.A. Arranz, A.I. Arroba, A.M. Valverde, R. Simó, Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 65(1), 172–187 (2016)PubMed

24.

A.R. Santos, L. Ribeiro, F. Bandello, R. Lattanzio, C. Egan, U. Frydkjaer-Olsen, J. García-Arumí, J. Gibson, J. Grauslund, S.P. Harding, G.E. Lang, P. Massin, E. Midena, P. Scanlon, S.J. Aldington, S. Simão, C. Schwartz, B. Ponsati, M. Porta, M.A. Costa, C. Hernández, J. Cunha-Vaz, R. Simó, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR), Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project. Diabetes 66(9), 2503–2510 (2017)CrossRefPubMed

25.

R. Simó, F. Bandello, C. Egan, J. García-Arumí, J. Gibson, J. Grauslund, S.P. Harding, G.E. Lang, P. Massin, E. Midena, P. Scanlon, B. Ponsati, M. Porta, L. Ribeiro, C. Hernández, J. Cunha-Vaz, The European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Topical administration of somatostatin and brimonidine in the early stages of diabetic retinopathy: results of the EUROCONDOR study. Diabetologia 60(Suppl 1), 1 (2017). https://doi.org/10.1007/s00125-017-4350-z

26.

M. Trento, O. Durando, S. Lavecchia, L. Charrier, F. Cavallo, M.A. Costa, C. Hernández, R. Simó, M. Porta, EUROCONDOR trial investigators, Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial. Endocrine 57(1), 83–88 (2017)CrossRefPubMed

Title: Somatostatin and diabetic retinopathy: an evolving story
Authors: Olga Simó-Servat
Cristina Hernández
Rafael Simó
Publication date: 01-04-2018
Publisher: Springer US
Published in: Endocrine / Issue 1/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1561-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Somatostatin and diabetic retinopathy: an evolving story

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

MiR-145 improves macrophage-mediated inflammation through targeting Arf6

G3 GEP NENs category: are basic and clinical investigations well integrated?

Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy

Chronic apelin treatment improves hepatic lipid metabolism in obese and insulin-resistant mice by an indirect mechanism

Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats

Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page